Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 29...
Revenue of $3,814 million GAAP Net Income of $363 million, Adjusted EBITDA of $887 million GAAP Diluted Earnings per Share of $1.97, Adjusted D...
Shanghai Junshi Biosciences Co., a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercializati...
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncology Further data read-outs expected in 2024 in oncology, mental health, ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced that it awarded a total of $1.5 million to 28 organiza...
net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entr...
In this insightful interview with Martin Westberg, Vice President and General Manager of Cell Therapy at Cytiva, BioPharma BoardRoom delve into the tr...
Financial results of Q1 2024 Healthcare with strong performance Electronics increases sales and earnings organically, driven by higher demand for semic...
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 bil...
First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023...
In an interview with BioPharma BoardRoom, Cem Zorlular, CEO of Er-Kim, shares his personal journey and the driving force behind Er-Kim's mission to...
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today ...
Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16...
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 Net ...
© 2024 Biopharma Boardroom. All Rights Reserved.
